Soligenix, Inc. (NASDAQ:SNGX) Sees Large Increase in Short Interest

Soligenix, Inc. (NASDAQ:SNGX) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totalling 44,400 shares, an increase of 21.0% from the November 30th total of 36,700 shares. Based on an average daily volume of 105,000 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.8% of the shares of the company are sold short.

Institutional Trading of Soligenix

A hedge fund recently bought a new stake in Soligenix stock. Armistice Capital LLC acquired a new stake in Soligenix, Inc. (NASDAQ:SNGX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 80,000 shares of the biopharmaceutical company’s stock, valued at approximately $206,000. Armistice Capital LLC owned 8.11% of Soligenix at the end of the most recent quarter. 3.60% of the stock is owned by institutional investors and hedge funds.

Soligenix Stock Performance

Soligenix stock opened at $2.91 on Tuesday. Soligenix has a 52 week low of $1.83 and a 52 week high of $19.20. The firm has a market capitalization of $7.30 million, a PE ratio of -0.39 and a beta of 1.79. The business’s 50-day simple moving average is $3.40 and its 200-day simple moving average is $3.81.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.